4 results
Primary Objective:* To evaluate the safety of TAK-164 and to determine the MTD and/or RP2D.Part C (imaging substudy) secondary objectives are:* To determine the biodistribution of 89Zr-TAK-164 in patients with mCRC and/or metastatic gastric…
Main objective:To improve the functional neurological outcome of patients, as measured on the Raschbuilt Overall Disability Scale (RODS) for inflammatory neuropathies (iRODS) with Zanubrutinib in combination with standard treatment with Rituximab or…
To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for zanubrutinib
Primary:• To compare the efficacy of zanubrutinib (also known as BGB-3111) versus ibrutinib as measured by overall response rate determined by investigator assessment Secondary:• To compare the efficacy of zanubrutinib versus ibrutinib as measured…